Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Endocrinology · ACTH-Producing Pancreatic Neuroendocrine Tumor

Survivorship: Healing After Cortisol Excess

At a Glance

Recovery after an ACTH-producing pancreatic neuroendocrine tumor requires long-term surveillance and may involve a slow hydrocortisone taper while adrenal function returns. Ongoing care can address bone loss, diabetes, digestive problems, and liver health.

Moving into survivorship after an ACTH-producing pancreatic neuroendocrine tumor (pNET) is a transition from “crisis management” to “long-term vigilance.” While the immediate hormone storm has passed, your body requires time to heal from the profound effects of hypercortisolism and the impact of pancreatic surgery [1][2].

Monitoring for Recurrence

Because these specific tumors can be aggressive or return years later, long-term surveillance is vital [3].

  • Imaging: Your team will likely schedule periodic contrast-enhanced CT or MRI scans [4]. If your tumor was seen on a DOTATATE PET scan previously, that may be used again to check for new growth [3].
  • Biochemical Markers: Doctors will continue to monitor your ACTH and cortisol levels [1]. A rising ACTH level is sometimes a sign that tumor cells have returned, though this marker can be difficult to interpret during steroid replacement and is expected to be high if you had a bilateral adrenalectomy [5][6].
  • The 5-Year Myth: While many cancer protocols end after five years, neuroendocrine survivors often require longer monitoring (10 years or more) because of the risk of late recurrence [4][3].

The Adrenal “Wake-Up” Period

For months or even years, your tumor forced your adrenal glands to work at maximum capacity. This high-stress state caused your brain’s natural control system—the hypothalamic-pituitary-adrenal (HPA) axis—to “shut down” [7][2].

  • Secondary Adrenal Insufficiency: Once the tumor is gone, your brain and adrenals may “forget” how to make cortisol on their own. You will need to take hydrocortisone replacement therapy during this period [8].
  • The Taper: Recovery is slow. While some estimates suggest a median of 14 to 17 months for the axis to fully recover, this varies widely from months to years depending on the individual [9][10]. Your doctor will gradually lower your dose based on morning cortisol blood tests and ACTH stimulation tests [11][10].
  • Glucocorticoid Withdrawal: As you lower your dose, you may feel “flu-like” symptoms, joint pain, or low mood. This is often a sign of your body adjusting to lower (but normal) cortisol levels, but it must be distinguished from a dangerous adrenal crisis [12][7].

Managing Lingering Damage

The hormone excess may leave behind health challenges that require ongoing care:

  • Skeletal Fragility: High cortisol aggressively thins the bones. You may need a DEXA scan to check for osteoporosis and may require specialized bone-building medications along with Calcium and Vitamin D [13][14].
  • Persistent Diabetes: While blood sugar often improves after cortisol drops, some patients develop permanent Type 3c diabetes (pancreatogenic diabetes) due to the loss of pancreatic tissue during surgery [15][16]. This can be more “brittle” (unpredictable) than common Type 2 diabetes [15].
  • Exocrine Pancreatic Insufficiency (EPI): If a large portion of your pancreas was removed, you may not produce enough enzymes to digest food. Symptoms include oily stools, bloating, and weight loss [17][18]. This is managed with Pancreatic Enzyme Replacement Therapy (PERT) taken with every meal [17].
  • Liver Health: Some patients (reported at about 20% in certain mixed surgical cohorts) develop new-onset MASLD/MASH (previously known as fatty liver disease) [19]. Regular monitoring of liver enzymes and imaging is part of long-term care [20].

Survivorship Checklist

  • Medical Alert: Wear a bracelet stating “Adrenal Insufficiency - Needs Hydrocortisone” until your HPA axis is proven to have recovered [21].
  • Sick-Day Rules: Ensure you and your family have a clinician-approved written plan for when to increase your steroid dose (e.g., during high fever or injury) and how to use an emergency injection kit when you cannot keep pills down [21].
  • Nutrition: Work with a dietitian to manage EPI and ensure you are absorbing fat-soluble vitamins (A, D, E, and K) [14].
  • Strength: Engage in physical activity to help your muscles and bones recover, but seek supervised rehabilitation if your bones are fragile [13].

Common questions in this guide

How long will I need follow-up after an ACTH-producing pancreatic neuroendocrine tumor?
Follow-up often lasts longer than the standard five-year window because these tumors can recur years after treatment. Your team may use periodic CT or MRI scans, sometimes DOTATATE PET if it was useful before, along with ACTH and cortisol tests. The exact schedule depends on your tumor and treatment history.
Why do I need hydrocortisone after my tumor was removed?
Long-term cortisol excess can suppress the brain-adrenal system that normally signals the adrenal glands to make cortisol. Hydrocortisone replaces this hormone while adrenal function recovers, and clinicians usually adjust it using morning cortisol and, when appropriate, ACTH stimulation testing. Never change or stop it without medical instructions.
How can I tell steroid withdrawal from adrenal insufficiency?
During a hydrocortisone taper, flu-like symptoms, joint pain, and low mood can occur as the body adjusts to lower cortisol levels. These symptoms can overlap with adrenal insufficiency, so your clinician must assess them rather than relying on symptoms alone. Follow your written sick-day plan and seek urgent help for suspected adrenal crisis.
Should I be checked for bone loss after cortisol excess?
Prolonged high cortisol can weaken bones and cause osteoporosis. Ask your clinician whether a DEXA scan is appropriate and whether you need calcium, vitamin D, or a bone-building medicine. Exercise can help, but activity should be supervised if your bones are fragile.
What digestive problems can happen after pancreatic surgery?
Removing pancreatic tissue can cause exocrine pancreatic insufficiency, which may lead to oily stools, bloating, or weight loss because the body lacks enough digestive enzymes. Pancreatic enzyme replacement therapy, taken with every meal, can help digestion. Ongoing symptoms should be evaluated, especially if blood sugar is also difficult to control.
What should I do during illness while taking hydrocortisone?
Until adrenal recovery is confirmed, wear medical alert identification and keep an emergency hydrocortisone kit available. Ask your clinician for a written sick-day plan explaining when to increase the dose and how to use the emergency injection if you cannot keep pills down. Family members should know the plan too.
How will my diabetes and liver health be monitored?
Blood sugar may remain high or become unpredictable after pancreatic surgery because loss of pancreatic tissue can cause type 3c diabetes. Your team may also monitor liver enzymes and use imaging for MASLD or MASH, forms of fatty liver disease that can occur during long-term follow-up. The schedule should be individualized.

Get notified when new evidence is published on pancreatic ACTH-producing neuroendocrine tumor.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (21)
  1. 1

    Pancreatic ACTH Hypersecretion and Pituitary Macroadenoma.

    Bettale CM, Allen JW, Mahdi ZK, Ioachimescu AG

    JCEM case reports 2023; (1(1)):luad007 doi:10.1210/jcemcr/luad007.

    PMID: 37908262
  2. 2

    Rapid Adrenal Atrophy Following Excision of an Ectopic Adrenocorticotropin-Secreting Lung Carcinoid Tumor.

    Mohamed E, Osman W, Papadopoulou D, et al.

    JCEM case reports 2025; (3(10)):luaf180 doi:10.1210/jcemcr/luaf180.

    PMID: 40860572
  3. 3

    Metastatic insulinoma presenting 14 years after benign tumour resection: a rare case and management dilemma.

    Keen F, Iqbal F, Owen P, et al.

    Endocrinology, diabetes & metabolism case reports 2020; (2020()).

    PMID: 33434180
  4. 4

    Imaging of Pancreatic Neuroendocrine Neoplasms.

    Chiti G, Grazzini G, Cozzi D, et al.

    International journal of environmental research and public health 2021; (18(17)) doi:10.3390/ijerph18178895.

    PMID: 34501485
  5. 5

    Pancreatic Neuroendocrine Tumor Secreting Vasoactive Intestinal Peptide and Dopamine With Pulmonary Emboli: A Case Report.

    Nilubol N, Freedman EM, Quezado MM, et al.

    The Journal of clinical endocrinology and metabolism 2016; (101(10)):3564-3567 doi:10.1210/jc.2016-2051.

    PMID: 27583474
  6. 6

    Metastatic Pancreatic Neuroendocrine Tumor that Progressed to Ectopic Adrenocorticotropic Hormone (ACTH) Syndrome with Growth Hormone-releasing Hormone (GHRH) Production.

    Tadokoro R, Sato S, Otsuka F, et al.

    Internal medicine (Tokyo, Japan) 2016; (55(20)):2979-2983 doi:10.2169/internalmedicine.55.6827.

    PMID: 27746436
  7. 7

    Hypothalamic-pituitary-adrenal axis recovery after treatment of Cushing's syndrome.

    Balasko A, Zibar Tomsic K, Kastelan D, Dusek T

    Journal of neuroendocrinology 2022; (34(8)):e13172 doi:10.1111/jne.13172.

    PMID: 35726348
  8. 8

    Factors predicting the duration of adrenal insufficiency in patients successfully treated for Cushing disease and nonmalignant primary adrenal Cushing syndrome.

    Prete A, Paragliola RM, Bottiglieri F, et al.

    Endocrine 2017; (55(3)):969-980 doi:10.1007/s12020-016-1007-5.

    PMID: 27395418
  9. 9

    Duration of adrenal insufficiency after surgical treatment of endogenous hypercortisolism: a prospective cohort study.

    Chacko SR, Ahmadian S, Sharma SS, et al.

    European journal of endocrinology 2026; (194(1)):1-12 doi:10.1093/ejendo/lvaf264.

    PMID: 41424030
  10. 10

    The Recovery of Hypothalamic-Pituitary-Adrenal Axis Is Rapid in Subclinical Cushing Syndrome.

    Kim HK, Yoon JH, Jeong YA, Kang HC

    Endocrinology and metabolism (Seoul, Korea) 2016; (31(4)):592-597 doi:10.3803/EnM.2016.31.4.592.

    PMID: 28029028
  11. 11

    Morning Serum Cortisol as a Predictor for the HPA Axis Recovery in Cushing's Disease.

    Cui Q, Liu D, Xiang B, et al.

    International journal of endocrinology 2021; (2021()):4586229 doi:10.1155/2021/4586229.

    PMID: 34527048
  12. 12

    Glucocorticoid Withdrawal Syndrome following treatment of endogenous Cushing Syndrome.

    He X, Findling JW, Auchus RJ

    Pituitary 2022; (25(3)):393-403 doi:10.1007/s11102-022-01218-y.

    PMID: 35471718
  13. 13

    Factors predicting prolonged glucocorticoid therapy in patients with adrenal insufficiency after laparoscopic adrenalectomy.

    Ziglioli F, Cataldo S, Cavalieri DM, et al.

    Annals of medicine and surgery (2012) 2022; (77()):103390 doi:10.1016/j.amsu.2022.103390.

    PMID: 35638023
  14. 14

    Diagnosis and risk factors in pancreatogenic diabetes.

    Sharma RK, Singh A, Dawra S

    Advances in clinical chemistry 2026; (131()):177-193 doi:10.1016/bs.acc.2025.10.003.

    PMID: 41708204
  15. 15

    Type 3c (pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer.

    Hart PA, Bellin MD, Andersen DK, et al.

    The lancet. Gastroenterology & hepatology 2016; (1(3)):226-237 doi:10.1016/S2468-1253(16)30106-6.

    PMID: 28404095
  16. 16

    Diabetes mellitus secondary to endocrine diseases: a position statement of the working group of the club of the Italian society of endocrinology (SIE)-Nutrition hormones and metabolism.

    Barrea L, Caprio M, Perrini S, et al.

    Journal of endocrinological investigation 2025; (48(8)):1739-1758 doi:10.1007/s40618-025-02589-2.

    PMID: 40293649
  17. 17

    Diagnosis and Management of Exocrine Pancreatic Insufficiency.

    Forsmark CE

    Current treatment options in gastroenterology 2018; (16(3)):306-315 doi:10.1007/s11938-018-0186-y.

    PMID: 30027527
  18. 18

    Long-term outcomes and risk factors of pancreatic insufficiency after a pancreatoduodenectomy: A retrospective study.

    Kato T, Watanabe Y, Oshima Y, et al.

    Surgery 2024; (176(3)):880-889 doi:10.1016/j.surg.2024.04.041.

    PMID: 38879380
  19. 19

    New onset non-alcoholic fatty liver disease after resection of pancreatic neuroendocrine tumors.

    Mackay TM, Genç CG, Takkenberg RB, et al.

    Journal of surgical oncology 2018; (117(7)):1548-1555 doi:10.1002/jso.25051.

    PMID: 29572825
  20. 20

    Metabolic Dysfunction-Associated Steatotic Liver Disease after Pancreatoduodenectomy: an Underestimated Metabolic Complication Driven by Unique Pathophysiological Mechanisms.

    Tehuitzil-Cordero A, Montalvo-Javé E, Uribe M, Nuño-Lámbarri N

    Journal of gastrointestinal cancer 2026; (57(1)):30 doi:10.1007/s12029-026-01409-x.

    PMID: 41627580
  21. 21

    Differences in morbidity and mortality between unilateral adrenalectomy for adrenal Cushing's syndrome and bilateral adrenalectomy for therapy refractory extra-adrenal Cushing's syndrome.

    Reibetanz J, Kelm M, Uttinger KL, et al.

    Langenbeck's archives of surgery 2022; (407(6)):2481-2488 doi:10.1007/s00423-022-02568-8.

    PMID: 35633419

This page is for informational purposes only and does not constitute medical advice. Your endocrinology and oncology teams should personalize surveillance, hydrocortisone dosing, and management of post-surgical complications.

Guide contents pancreatic ACTH-producing neuroendocrine tumor
Research & Literature
05 Treating the Tumor